Palmoplantaris Pustulosis, Psoriasis, Pustular Psoriasis of Palms and Soles, Pustulosis of Palms and Soles, Pustulosis Palmaris et Plantaris
Conditions
Keywords
safety, effectiveness, Alefacept, Palmar, Plantar, Pustulosis
Brief summary
The purpose of this study is to determine if Alefacept is effective in the treatment of palmar plantar pustulosis.
Detailed description
Palmar plantar pustulosis is a chronic, disabling skin condition which is difficult to treat since it is often recalcitrant to current treatments and associated with high recurrence rates. This condition appears to be a T lymphocyte mediated condition and is thought by some to be a subtype of psoriasis. Alefacept affects T cell activation and induces apoptosis of memory T cells. It has been shown to be efficacious in the treatment of psoriasis vulgaris and may be associated with prolonged remissions. There is extremely limited experience with use of Alefacept in Palmar Plantar Pustulosis. This pilot trial should provide additional information concerning its use for this indication.
Interventions
DRUGAlefacept
Sponsors
Biogen
The Guenther Dermatology Research Centre
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have stable, moderate, severe or very severe palmar plantar pustulosis. * Must have a minimum of at least 3 pustules on 1 sole or palm. * Must give written informed consent. * Subjects must be 18 years of age or older. * Adult Males and non-pregnant, non-lactating females. * Female subjects of childbearing potential must state that they are using measures to avoid conception through active means. * Subjects must be in general good health with no other skin disease, disease state or physical condition which would impair evaluation of palmar plantar pustulosis or which would increase their health risk by study participation. * Subjects must be willing to receive a 15 mg IM injection of Alefacept weekly for 16 weeks.
Exclusion criteria
* Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded. * Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy. * Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug. * Any subject whose CD4+ T-lymphocyte count at study entry is less than the lower limit of normal per reference laboratory. * Treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration. * Treatment with psoralen + ultraviolet A (PUVA), systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or mofetil or other systemic immunosuppressant agents within the 28 days prior to investigational drug administration. * Ultraviolet B (UVB) phototherapy within 14 days prior to investigational drug administration. * Treatment within 7 days with topical agents (e.g. tar, anthralin, calcipotriol, tazarotene, steroids) which might have an effect on palmar plantar pustulosis. * Known HIV, Hepatitis B or C seropositivity or tuberculosis infection. * Significant abnormal chemistry, i.e. liver function tests greater than 3 times the upper limit of normal. * Allergy to Alefacept or any of the components of the formulation. * Known malignancy or history of malignancy within the previous 5 years (with the exception of basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin that has been treated with no evidence of recurrence.) * Previous treatment with alefacept.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage change in PPPASI from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| number of subjects with no pustules | — |
| number of subjects with PPPASI 75 | — |
| number of subjects with PPPASI 50 | — |
| number of subjects with very mild/clear PGA | — |
Countries
Canada
Outcome results
None listed